Sanuwave Health (SNWV) to Release Quarterly Earnings on Friday

Sanuwave Health (NASDAQ:SNWV) is expected to be posting its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect Sanuwave Health to post earnings of ($0.05) per share and revenue of $9.65 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV) last posted its earnings results on Thursday, March 26th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.14). Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%. The company had revenue of $13.09 million for the quarter, compared to the consensus estimate of $13.23 million. On average, analysts expect Sanuwave Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sanuwave Health Stock Performance

Shares of SNWV stock opened at $15.64 on Wednesday. The company has a 50 day moving average price of $19.99 and a 200-day moving average price of $26.32. Sanuwave Health has a 52 week low of $15.35 and a 52 week high of $46.58. The firm has a market capitalization of $134.50 million, a PE ratio of -97.74 and a beta of 1.37. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 10.08.

Analysts Set New Price Targets

Several brokerages recently issued reports on SNWV. Wall Street Zen cut shares of Sanuwave Health from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Roth Mkm reiterated a “buy” rating and set a $47.00 target price (down from $53.00) on shares of Sanuwave Health in a research note on Monday, March 30th. Weiss Ratings upgraded Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, March 27th. Finally, Zacks Research lowered Sanuwave Health from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $51.00.

Hedge Funds Weigh In On Sanuwave Health

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new position in Sanuwave Health during the second quarter valued at $26,000. Charles Schwab Investment Management Inc. raised its stake in shares of Sanuwave Health by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 24,398 shares of the company’s stock worth $728,000 after buying an additional 1,135 shares during the period. Barclays PLC lifted its position in shares of Sanuwave Health by 12.7% during the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock valued at $346,000 after buying an additional 1,306 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Sanuwave Health during the 2nd quarter valued at about $46,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Sanuwave Health during the 3rd quarter valued at approximately $67,000. 42.53% of the stock is owned by institutional investors.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.